## Jana HroudovÃ;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/214238/publications.pdf Version: 2024-02-01



ΙΔΝΑ ΗΡΟΠΟΟΛΑ:

#	Article	IF	CITATIONS
1	Effects of Novel Tacrine Derivatives on Mitochondrial Energy Metabolism and Monoamine Oxidase Activity—In Vitro Study. Molecular Neurobiology, 2021, 58, 1102-1113.	4.0	5
2	Assessment of the Effects of Drugs on Mitochondrial Respiration. Methods in Molecular Biology, 2021, 2277, 133-142.	0.9	3
3	Effects of novel 17β-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration. Toxicology Letters, 2021, 339, 12-19.	0.8	7
4	Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World Journal of Psychiatry, 2021, 11, 277-296.	2.7	17
5	Huprine Y – Tryptophan heterodimers with potential implication to Alzheimer's disease treatment. Bioorganic and Medicinal Chemistry Letters, 2021, 43, 128100.	2.2	5
6	Effect of Novel Antipsychotics on Energy Metabolism — In Vitro Study in Pig Brain Mitochondria. Molecular Neurobiology, 2021, 58, 5548-5563.	4.0	12
7	Little in vitro effect of remdesivir on mitochondrial respiration and monoamine oxidase activity in isolated mitochondria. Toxicology Letters, 2021, 350, 143-151.	0.8	6
8	Measurement of Mitochondrial Respiration in Platelets. Methods in Molecular Biology, 2021, 2277, 269-276.	0.9	4
9	In vitro effects of antidepressants and mood-stabilizing drugs on cell energy metabolism. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 797-811.	3.0	12
10	Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer's disease and depressive disorder. Mitochondrion, 2019, 48, 67-77.	3.4	40
11	Disturbances of mitochondrial parameters to distinguish patients with depressive episode of bipolar disorder and major depressive disorder. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 233-240.	2.2	20
12	In vitro effects of antipsychotics on mitochondrial respiration. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1209-1223.	3.0	27
13	Plasma amyloid beta levels and platelet mitochondrial respiration in patients with Alzheimer's disease. Clinical Biochemistry, 2019, 72, 71-80.	1.9	23
14	Mitochondrial Dysfunction in Blood Platelets of Patients with Manic Episode of Bipolar Disorder. CNS and Neurological Disorders - Drug Targets, 2019, 18, 222-231.	1.4	11
15	Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission. Neuroscience, 2018, 370, 191-206.	2.3	48
16	Interactions Among Polymorphisms of Susceptibility Loci for Alzheimer's Disease or Depressive Disorder. Medical Science Monitor, 2018, 24, 2599-2619.	1.1	17
17	Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease. Current Alzheimer Research, 2018, 15, 938-950.	1.4	15
18	Biological hypotheses and biomarkers of bipolar disorder. Psychiatry and Clinical Neurosciences, 2017, 71, 77-103.	1.8	164

Jana HroudovÃi

#	Article	IF	CITATIONS
19	In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity. Molecular Neurobiology, 2017, 54, 5894-5904.	4.0	17
20	Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy. CNS and Neurological Disorders - Drug Targets, 2017, 16, 176-186.	1.4	27
21	Research of new drugs for Alzheimer's disease. Psychiatrie Pro Praxi, 2017, 18, 7-10.	0.1	2
22	Loss of mitochondrial DNAâ€encoded protein ND1 results in disruption of complex I biogenesis during early stages of assembly. FASEB Journal, 2016, 30, 2236-2248.	0.5	49
23	Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism. European Journal of Medicinal Chemistry, 2016, 121, 774-784.	5.5	56
24	The effect of prolonged simvastatin application on serotonin uptake, membrane microviscosity and behavioral changes in the animal model. Physiology and Behavior, 2016, 158, 112-120.	2.1	20
25	Mitochondrial Respiration in the Platelets of Patients with Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 930-941.	1.4	71
26	Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. Journal of Molecular Neuroscience, 2015, 56, 926-931.	2.3	59
27	Mitochondrial Dysfunctions in Neurodegenerative Diseases: Relevance to Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-9.	1.9	227
28	Capture of Somatic mtDNA Point Mutations with Severe Effects on Oxidative Phosphorylation in Synaptosome Cybrid Clones from Human Brain. Human Mutation, 2014, 35, 1476-1484.	2.5	12
29	Cannabinoid-induced changes in respiration of brain mitochondria. Toxicology Letters, 2014, 231, 62-71.	0.8	93
30	Plasma homocysteine in Alzheimer's disease with or without co-morbid depressive symptoms. Neuroendocrinology Letters, 2014, 35, 42-9.	0.2	8
31	Mitochondrial respiration in blood platelets of depressive patients. Mitochondrion, 2013, 13, 795-800.	3.4	90
32	Plasma cortisol in Alzheimer's disease with or without depressive symptoms. Medical Science Monitor, 2013, 19, 681-689.	1.1	41
33	Comparison of Novel Tacrine and 7-MEOTA Derivatives with Aromatic and Alicyclic Residues: Synthesis, Biological Evaluation and Docking Studies. Letters in Organic Chemistry, 2013, 10, 291-297.	0.5	3
34	Control mechanisms in mitochondrial oxidative phosphorylation. Neural Regeneration Research, 2013, 8, 363-75.	3.0	45
35	In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicology Letters, 2012, 213, 345-352.	0.8	74
36	In vitro effects of acetylcholinesterase reactivators on monoamine oxidase activity. Toxicology Letters, 2011, 201, 176-180.	0.8	10

Jana HroudovÃi

#	Article	IF	CITATIONS
37	Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry and Clinical Neurosciences, 2011, 65, 130-141.	1.8	51
38	A Transgenic Approach to Identify Thyroxine Transporter-Expressing Structures in Brain Development. Journal of Neuroendocrinology, 2011, 23, 1194-1203.	2.6	25
39	Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine—new tacrine derivate with cholinergic properties. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6563-6566.	2.2	21
40	In vitro effects of acetylcholinesterase inhibitors and reactivators on Complex I of electron transport chain. Neuroendocrinology Letters, 2011, 32, 259-63.	0.2	6
41	Synthesis and In Vitro Evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a Cholinesterase Inhibitor with Regard to Alzheimer's Disease Treatment. Molecules, 2010, 15, 8804-8812.	3.8	22
42	Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuroendocrinology Letters, 2010, 31, 336-42.	0.2	60
43	Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuroendocrinology Letters, 2010, 31, 645-56.	0.2	35